Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Your Profile Become a Member/Get Newsletter Contact Us
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by NARSAD, the Brain and Behavior Research Fund, and was created with funding from the U.S. National Institute of Mental Health.
Printable version  
SZGene - Gene overview of all published SZ-association studies for DRD3    
Back Search Methods Disclaimer Credits
 Gene: DRD3  (D3DR; ETM1; FET1)  Entrez Gene    View on AlzGene   View on PDGene
 Protein: dopamine receptor D3  (essential tremor 1)  ProteinLink
 Chromosome: 3   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 21 October 2010
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      SZ Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Anney, 2002
UK, Ireland CL  7  (detail)  368
(28%)
IV-46 + 13
(-)
368
(28%)
43 + 12
(-)
Negative
Asherson, 1996
UK (III) CL  1  (detail)  100
(22%)
M--100
(36%)
-Positive
Asherson, 1996
UK (I) CL  1  (detail)  72
(31%)
M--100
(36%)
-Positive
Asherson, 1996
UK (II) CL  1  (detail)  81
(27%)
M--100
(36%)
-Positive
Baritaki, 2004
Greece CL  1  (detail)  114
(41%)
IV25.5 + 9.2
(14-60)
50.6 + 13.3
(-)
192
(39%)
45.1 + 8.7
(-)
Negative
Barlas, 2008
Turkey CL  1  (detail)  92
(17%)
IV-30.4 + 10.5
(-)
100
(19%)
31.7 + 9.2
(-)
Negative
Betcheva, 2009
Bulgaria CL  8  (detail)  185
(-)
IV--184
(-)
-Negative
Costas, 2008
Spain CL  7  (detail)  273
(-)
IV-39.9 + 10.8
(18-60)
512
(-)
38.8 + 11.1
(18-60)
Trend
Crocq, 1992
UK CL  1  (detail)  68
(37%)
IIIR-43.1 + 13.7
(19-72)
68
(43%)
45.9 + 14.9
(20-83)
Positive
Crocq, 1992
France CL  1  (detail)  73
(27%)
IIIR-38.4 + 12
(20-69)
71
(41%)
33.9 + 8.9
(20-65)
Positive
Di Bella, 1994
Italy CL  1  (detail)  85
(45%)
IIIR21.8 + 5
(-)
33.6 + 11.3
(-)
78
(64%)
29 + 6.6
(-)
Negative
Dollfus, 1996
France PO  1  (detail)  62
(-)
M--161
(-)
-Negative
Domingeuz, 2006
Spain CL  17  (detail)  260
(35%)
IV--354
(55%)
-Trend
Durany, 1996
Spain CL  1  (detail)  107
(58%)
10-55 + 16
(-)
100
(59%)
53 + 21
(-)
Negative
Ebstein, 1997
Italy CL  1  (detail)  80
(24%)
IIIR20.8 + 4.6
(13-34)
31.2 + 9.5
(14-64)
63
(51%)
36.5 + 10.6
(27-69)
Positive
Ebstein, 1997
Israel CL  1  (detail)  87
(37%)
IIIR20.9 + 4.9
(13-34)
39.3 + 11.3
(19-71)
136
(49%)
32.9 + 11.5
(18-80)
Positive
Fathalli, 2007
Canada (Montreal) CL  1  (detail)  194
(28%)
M--89
(60%)
-Negative
Fathalli, 2007
Canada (Ottawa) CL  1  (detail)  50
(14%)
M--29
(45%)
-Negative
Fathalli, 2007
Tunisia, Hungary CL  1  (detail)  164
(29%)
M--54
(24%)
-Negative
Gaitonde, 1996
UK CL  1  (detail)  84
(45%)
U23.5 + 6.4
(16-49)
44.3 + 14.8
(-)
77
(48%)
41.7 + 19
(-)
Negative
Gourion, 2005
France CL  1  (detail)  210
(32%)
IV21.6 + 4.8
(-)
31.4 + 8.5
(-)
99
(54%)
30.5 + 9.9
(-)
Negative
Griffon, 1996
France CL  1  (detail)  119
(-)
IIIR--85
(-)
-Positive
Griffon, 1996
Overlaps with
Crocq, 1992 (France)
CL  1  (detail)  119
(-)
IIIR--85
(-)
-n.a.
Hawi, 1998
Ireland CL  1  (detail)  198
(32%)
IIIR--235
(44%)
-Negative
Jonsson, 1993
Overlaps with
Jonsson, 2003
CL  1  (detail)  76
(32%)
IIIR-47
(20-90)
53
(38%)
39
(29-55)
n.a.
Jonsson, 1999
Sweden CL  2  (detail)  110
(35%)
IIIR-45.5
(20-90)
83
(41%)
38.1
(26-56)
Trend
Jonsson, 2003
Sweden CL  1  (detail)  156
(39%)
IIIR-42.7 + 16.9
(-)
442
(44%)
40.9 + 12.3
(-)
Negative
Jonsson, 2004
Germany CL  1  (detail)  649
(46%)
IV-38.7 + 12.2
(-)
584
(20%)
30.2 + 7.6
(-)
Negative
Joober, 2000
Overlaps with
Fathalli, 2007
CL  1  (detail)  106
(29%)
IV-39.5 + 8.3
(-)
89
(-)
-n.a.
Kennedy, 1995
Italy CL  1  (detail)  97
(-)
IIIR--64
(-)
-Trend
Krebs, 1998
Overlaps with
Gourion, 2005
CL  1  (detail)  89
(38%)
IIIR-33.3 + 9.2
(-)
52
(50%)
35.4 + 10
(-)
n.a.
Lafuente, 2008
Spain CL  1  (detail)  243
(46%)
IV-34 + 13
(-)
291
(62%)
61.7 + 11
(-)
Negative
Laurent, 1994
France CL  1  (detail)  76
(28%)
IIIR-42 + 12.3
(-)
86
(42%)
48 + 8.3
(-)
Negative
Lorenzo, 2006
Spain CL  1  (detail)  178
(-)
IV--132
(-)
-Negative
Mant, 1994
UK CL  1  (detail)  66
(42%)
IIIR-46.6 + 16.8
(-)
97
(44%)
46.6 + 19.8
(-)
Positive
Mas, 2009
Overlaps with
Lafuente, 2008
CL  12  (detail)  159
(-)
IV--373
(54%)
51.9 + 19
(-)
Negative
Maziade, 1997
Canada CL  1  (detail)  70
(26%)
IIIR19.6 + 4.6
(-)
-79
(-)
44.2 + 13.6
(-)
Positive
Meszaros, 2000
Austria CL  1  (detail)  72
(39%)
IIIR-30.5 + 11.8
(-)
120
(63%)
33.6 + 8.1
(-)
Negative
Nimgaonkar, 1993
Overlaps with
Nimgaonkar, 1996 (Pittsburgh I)
CL  1  (detail)  53
(38%)
IIIR-37.8 + 11.4
(-)
61
(52%)
30.5 + 9.5
(-)
n.a.
Nimgaonkar, 1996
USA (Pittsburgh I) CL  1  (detail)  65
(40%)
IIIR-37.2 + 10.8
(-)
165
(-)
-Trend
Nimgaonkar, 1996
USA (Houston) CL  1  (detail)  50
(72%)
IIIR-37.2 + 9.9
(-)
51
(-)
-Negative
Nothen, 1993a
Overlaps with
Rietschel, 1996
CL  1  (detail)  111
(-)
U--100
(-)
-n.a.
Nothen, 1993b
Overlaps with
Nothen, 1993a
CL  1  (detail)  60
(33%)
IIIR25.2 + 8
(14-46)
34.8 + 11
(-)
60
(47%)
28.2 + 5.2
(-)
n.a.
Nothen, 1993b
Germany CL  1  (detail)  60
(33%)
IIIR25.2 + 8
(14-46)
34.8 + 11
(-)
60
(47%)
28.2 + 5.2
(-)
Negative
Rietschel, 1996
Germany CL  1  (detail)  146
(40%)
IIIR-32.6 + 10.1
(-)
100
(49%)
30.2 + 9.3
(-)
Negative
Rybakowski, 2001
Poland CL  1  (detail)  119
(38%)
M-30
(18-63)
85
(53%)
27
(22-60)
Negative
Sabate, 1994
France PO  2  (detail)  50
(-)
IIIR--50
(-)
-Negative
Saiz, 2009
Spain CL  1  (detail)  288
(40%)
IV-36.3 + 12.4
(-)
421
(49%)
40.6 + 11.3
(-)
Positive
Segman, 1999
Israel CL  1  (detail)  137
(39%)
IV-50.7 + 11.1
(-)
117
(53%)
44 + 9.4
(-)
Positive
Segman, 2000
Overlaps with
Segman, 1999
CL  1  (detail)  115
(48%)
IV--97
(53%)
-n.a.
Shaikh, 1996
UK CL  1  (detail)  133
(-)
IIIR--109
(-)
-Positive
Sivagnanasundaram, 2000
Overlaps with
Gaitonde, 1996
CL  1  (detail)  73
(-)
IIIR--56
(-)
-n.a.
Sivagnanasundaram, 2000
UK CL  3  (detail)  73
(-)
IIIR--56
(-)
-Positive
Spurlock, 1998
UK CL  1  (detail)  31
(-)
IIIR--31
(-)
-Positive
Spurlock, 1998
Sweden CL  1  (detail)  67
(-)
IIIR--71
(-)
-Positive
Spurlock, 1998
Portugal CL  1  (detail)  76
(-)
IIIR--33
(-)
-Positive
Spurlock, 1998
Ireland CL  1  (detail)  36
(-)
IIIR--83
(-)
-Positive
Spurlock, 1998
France CL  1  (detail)  30
(-)
IIIR--31
(-)
-Positive
Spurlock, 1998
Austria CL  1  (detail)  71
(-)
IIIR--57
(-)
-Positive
Staddon, 2005
Spain CL  3  (detail)  118
(36%)
IV23.7 + 8
(-)
40.6 + 14.4
(-)
162
(50%)
-Positive
Szekeres, 2004
Hungary CL  1  (detail)  75
(55%)
IV--45
(62%)
36.4 + 12.8
(-)
Negative
Talkowski, 2006
Overlaps with
Talkowski, 2008
CL  13  (detail)  331
(-)
IV--274
(55%)
-Positive
Talkowski, 2008
USA CL  18  (detail)  478
(-)
IV--501
(-)
-Positive
Ventriglia, 2002
Italy CL  1  (detail)  114
(-)
IV--138
(-)
-Positive
Virgos, 2001
Spain CL  1  (detail)  262
(40%)
9-61.4
(19-90)
278
(39%)
54.2
(21-90)
Negative
Zai, 2010
Canada CL  15  (detail)  167
(37%)
IV-37.5 + 10.8
(-)
167
(37%)
-Negative
 African Descent
Nimgaonkar, 1996
USA (Pittsburgh II) CL  1  (detail)  65
(55%)
IIIR-37.2 + 9.9
(-)
123
(-)
-Negative
 Asian
Chen, 1997
Taiwan CL  1  (detail)  178
(46%)
IIIR-47
(-)
100
(53%)
45
(-)
Negative
Fujiwara, 1997
Japan CL  1  (detail)  52
(-)
M--36
(-)
-Negative
Inada, 1995
Japan CL  1  (detail)  113
(52%)
U-50
(22-86)
48
(50%)
54
(20-80)
Negative
Ishiguro, 2000
Japan (II) CL  1  (detail)  99
(47%)
M-47.8 + 9.8
(-)
132
(45%)
48.5 + 11.3
(-)
Positive
Ishiguro, 2000
Japan (I) CL  4  (detail)  153
(42%)
M-45.3 + 12.1
(-)
122
(52%)
47.2 + 10.5
(-)
Positive
Iwata, 2003
Japan CL  2  (detail)  51
(57%)
IV13.5 + 1.7
(9-16)
20 + 7
(-)
148
(56%)
21 + 7
(-)
Negative
Ma, 2008
China CL  1  (detail)  329
(38%)
IV-47 + 11.3
(-)
288
(45%)
35 + 8.1
(-)
Negative
Morimoto, 2002
Japan CL  1  (detail)  48
(-)
10--48
(-)
-Positive
Nanko, 1993
Japan CL  1  (detail)  91
(45%)
IIIR-35.7 + 10.7
(19-63)
90
(48%)
27.8 + 6.4
(19-54)
Negative
Nunokawa, 2009
Japan (I) CL  16  (detail)  595
(47%)
IV-40.2 + 14.1
(-)
598
(48%)
38.1 + 10.5
(-)
Negative
Nunokawa, 2009
Japan (II) CL  4  (detail)  2126
(47%)
IV-47.3 + 14.3
(-)
2228
(47%)
46.6 + 13.9
(-)
Negative
Ohara, 1996
Japan CL  1  (detail)  153
(50%)
IV26.3 + 9.5
(-)
46.3 + 16
(-)
121
(58%)
34.4 + 14.1
(-)
Negative
Saha, 1994
Singapore CL  1  (detail)  137
(0%)
9-35.6
(-)
125
(0%)
38
(-)
Negative
Tanaka, 1996
Overlaps with
Nunokawa, 2009
CL  1  (detail)  100
(48%)
IIIR-44.2 + 12
(15-70)
100
(29%)
42.7 + 23.7
(22-86)
n.a.
Utsunomiya, 2008
Japan CL  1  (detail)  246
(48%)
IV-51.1 + 11.2
(-)
198
(47%)
55 + 6.3
(-)
Positive
Yang, 1993
China CL  1  (detail)  107
(33%)
RDC-28.8 + 7.9
(15-53)
98
(36%)
25 + 6.9
(19-50)
Negative
 Other/Mixed
Kennedy, 1995
USA, Canada CL  1  (detail)  117
(-)
IIIR--188
(-)
-Trend
Lovlie, 2001
India CL  1  (detail)  56
(48%)
IV-45.5 + 16
(-)
22
(45%)
43 + 15
(-)
Negative
Semwal, 2002
India CL  1  (detail)  536
(44%)
IV-22.8 + 7
(-)
936
(47%)
32.9 + 12.7
(-)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Ambrosio, 2004
Portugal  1  (detail)  9090
(36%)
IV--180
(50%)
-Negative
Fallin, 2005
USA  5  (detail)  263274
(26%)
IV19.5 + 4.5
(-)
-548
(50%)
-Negative
Fathalli, 2007
Overlaps with
Fathalli, 2007 (CC)
 1  (detail)  183-M----n.a.
Kalsi, 1998
UK, Iceland  1  (detail)  23113
(-)
IIIR--262
(-)
-Negative
Macciardi, 1994
Italy  1  (detail)  4242
(26%)
IIIR-26
(19-45)
84
(50%)
-Negative
Talkowski, 2006
USA  13  (detail)  151151
(-)
IV--302
(50%)
-Positive
Talkowski, 2008
Bulgaria  18  (detail)  659659
(50%)
IV--1318
(50%)
-Negative
Zai, 2010
Canada, USA  15  (detail)  95-IV----Negative
 Other/Mixed
Kremer, 2000
Palestine  1  (detail)  129129
(32%)
IV-28.9 + 8.2
(16-51)
258
(50%)
-Negative
Malhotra, 1998
USA  1  (detail)  5858
(28%)
IIIR-35.5 + 7.1
(-)
116
(50%)
-Negative
Prasad, 1999
India  1  (detail)  66-IV----Negative
Rothschild, 1996
USA  1  (detail)  71-IIIR----Negative
Talkowski, 2006
India  11  (detail)  141141
(-)
IV--282
(50%)
-Positive
Williams, 1998
Europe  1  (detail)  5757
(39%)
IIIR--114
(50%)
-Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine SZ diagnosis ->  "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Research Participants
Collaborators
Copyright © 2005-2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright